Sustainability Report 2010 Lek d.d.

Lek Sustainability Report for 2010 Lek Pharmaceuticals d.d., Verov‰kova 57, 1526 Ljubljana, Slovenia • /www.lek.si The 2010 report on sustainable operations by Lek Pharma- ceuticals, a Sandoz company, uses for the first time the re- porting requirements of the Responsible Care Initiative (RCI) and the EMAS Eco-Management Scheme, complementing them with the GRI Guidelines at a “C” application level. As a Sandoz company, Lek Pharmaceuticals is also a mem- ber of the Novartis Group, one of the global leaders in corpo- rate citizenship and sustainable development reporting. Lek reports regularly and comprehensively to Novartis, which in turn performs internal controls and assesses the conformity of the indicators. Lek’s data for a broader set of indicators is thus included in the aggregate data of the Novartis corporate reports. (Please visit www.novartis.com , www.corporateciti- zenship.novartis.com and www.novartisfoundation.org ) . Lek was inspired by both the Novartis Corporate Citizenship Policy and by its search for application solutions of optimum rationality to prepare an expanded report fulfilling the report- ing requirements of the RCI, EMAS Scheme and GRI Guide- lines. Lek thereby wishes to implement the Novartis policy in Slovenia, the country where it operates, as a visible and accountable member of local and national communities. REPORTING IN ACCORDANCE WITH RCI REQUIREMENTS Lek’s reporting has been based on the RCI for several years now, the present report being an upgrade of the previous reporting model. REPORTING IN ACCORDANCE WITH EMAS ECO-MANAGEMENT SCHEME REQUIREMENTS The report meets the requirements of Annex IV to Regulation No. 1221/2009 (EMAS), disclosing them also at the site level. REPORTING IN ACCORDANCE WITH GRI GUIDELINES Lek’s reporting in compliance with the GRI Guidelines uses reporting guidelines at the “C” application level (self-declared).